Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TransMedics Group, Inc.TMDX · Entity 4261 | Chief Commercial Officer | February 18, 2026 | February 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TransMedics Group, Inc.
Report date February 18, 2026 · Filed February 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,057 |
Reported balance
After 2026-02-18 transaction · row 1
1 source rowRow 1 · 2026-02-18 · Grant · Acquired 11,082 · Balance 19,057 F1: Consists of 11,082 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $135.50 · Expires 2036-02-18 | Direct | 16,734 |
Reported balance
After 2026-02-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-18 · Grant · Acquired 16,734 · Balance 16,734 F2: The option vests as to 25% of the shares underlying the option on February 18, 2027 and as to the remaining shares in equal monthly installments over three years thereafter, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of 11,082 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F2: The option vests as to 25% of the shares underlying the option on February 18, 2027 and as to the remaining shares in equal monthly installments over three years thereafter, subject to continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2026 Filed Feb 20, 2026 21:07 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GrantStock Option (Right to Buy) · Derivative | 16,734 | $0.00 Strike: $135.50 | $0.00 |
DisclosureSEC source: 0001193125-26-061341 · ownership.xml · derivative · entry 2 Cecere Giovanni · CIK 0002110539 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,734 Underlying: Common Stock · 16,734 shares Expires 2036-02-18 F2 · derivative.exercise_date: The option vests as to 25% of the shares underlying the option on February 18, 2027 and as to the remaining shares in equal monthly installments over three years thereafter, subject to continued service. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:07 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GrantCommon Stock | 11,082 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-061341 · ownership.xml · nonDerivative · entry 1 Cecere Giovanni · CIK 0002110539 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,057 F1 · shares: Consists of 11,082 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.